**Table e-1: chi-square test**

| Variable | Level | Completed recurrent stroke survey N (%) | Did not complete recurrent stroke survey N (%) | Total | P-value (based chi-square) |
|---|---|---|---|---|---|
| **Total** | | **329** | **160** | **489** | |
| Gender | Male | 173 (53%) | 85 (53%) | 258 | 0.91 |
| | Female | 156 (47%) | 75 (47%) | 231 | |
| Race | White non-hispanic | 263 (80%) | 132 (83%) | 395 | 0.75 |
| | Black | 19 (6%) | 6 (4%) | 25 | |
| | Other | 44 (13%) | 20 (13%) | 64 | |
| | Unknown | 3 (<1%) | 2 (1%) | 5 | |
| Age at cancer diagnosis, years | 0-4 | 116 (35%) | 49 (31%) | 165 | 0.58 |
| | 5-9 | 76 (23%) | 41 (26%) | 117 | |
| | 10-14 | 69 (21%) | 40 (25%) | 109 | |
| | 15-20 | 68 (21%) | 30 (19%) | 98 | |
| Age at first stroke, years | 0-17 | 142 (43%) | 69 (43%) | 211 | 0.20 |
| | 18-29 | 66 (20%) | 28 (18%) | 94 | |
| | 30-39 | 70 (21%) | 30 (19%) | 100 | |
| | $\geq$40 | 32 (10%) | 14 (9%) | 46 | |
| | Unknown | 19 (6%) | 19 (12%) | 38 | |
| Age at last followup or death, years | 0-17 | 22 (7%) | 13 (8%) | 35 | 0.48 |
| | 18-29 | 91 (28%) | 51 (32%) | 142 | |
| | 30-39 | 122 (37%) | 60 (38%) | 182 | |
| | $\geq$40 | 94 (29%) | 36 (23%) | 130 | |
| Cancer diagnosis | Brain tumor | 140 (43%) | 61 (38%) | 201 | 0.68 |
| | Leukemia | 90 (27%) | 51 (32%) | 141 | |
| | Hodgkins | 35 (11%) | 15 (9%) | 50 | |
| | Other | 64 (19%) | 33 (21%) | 97 | |
| Cranial radiation therapy maximum dose* | None | 55 (18%) | 25 (19%) | 80 | 0.15 |
| | 1-29 Gy | 55 (18%) | 32 (24%) | 87 | |
| | 30-49 Gy | 30 (10%) | 16 (12%) | 46 | |
| | 50+ Gy | 97 (31%) | 27 (21%) | 124 | |
| | Indirect | 52 (17%) | 18 (14%) | 70 | |
| | Unknown | 21 (8%) | 13 (10%) | 82 | |

- Among those with complete medical records abstraction